Q-omics provides the consensus-scored C7orf25 profile across patient tissues and cancer cell-line models. C7orf25 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, C7orf25 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, C7orf25 protein abundance shows 20,803 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight KICH, THCA, and UCEC as cancer lineages where C7orf25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C7orf25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C7orf25 survival associations across molecular data types. C7orf25 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C7orf25 RNA expression–survival associations across cancer types. High C7orf25 expression shows unfavorable associations in KICH, UVM, MESO and GBM, but favorable associations in LUSC and BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for C7orf25 RNA expression.
This table summarizes C7orf25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C7orf25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C7orf25 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, BLCA, LIHC and STAD. The THCA box plot shows higher C7orf25 RNA expression in normal versus tumor tissue (log2 FC = −0.296, t-test p < 0.001).
This table shows molecular features associated with C7orf25 in patient tissues and cancer cell lines. In patient samples, C7orf25 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, C7orf25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
